From: <Saved by Blink>
Snapshot-Content-Location: https://onlineconvertfree.com/upload/converter/210520/MTnVbQ0/Treatment_of_Hypertension.html
Subject: Diphtheria
Date: Thu, 21 May 2020 17:35:14 -0000
MIME-Version: 1.0
Content-Type: multipart/related;
	type="text/html";
	boundary="----MultipartBoundary--Vu8lxH1io5xnESpoEpOt15FWjOlBHgKeVZoPzvcDIJ----"


------MultipartBoundary--Vu8lxH1io5xnESpoEpOt15FWjOlBHgKeVZoPzvcDIJ----
Content-Type: text/html
Content-ID: <frame-54B4B4C2F80B831DFC80BB05C4476537@mhtml.blink>
Content-Transfer-Encoding: binary
Content-Location: https://onlineconvertfree.com/upload/converter/210520/MTnVbQ0/Treatment_of_Hypertension.html

<!--?xml version="1.0" encoding="UTF-8"?--><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.1 plus MathML 2.0//EN" "http://www.w3.org/Math/DTD/mathml2/xhtml-math11-f.dtd"><html xmlns="http://www.w3.org/1999/xhtml"><!--This file was converted to xhtml by LibreOffice - see https://cgit.freedesktop.org/libreoffice/core/tree/filter/source/xslt for the code.--><head profile="http://dublincore.org/documents/dcmi-terms/"><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><link rel="stylesheet" type="text/css" href="cid:css-37ae82ae-fc0a-4716-88c5-194d8658c832@mhtml.blink" /><title xml:lang="en-US">Diphtheria</title><meta name="DCTERMS.title" content="Diphtheria" xml:lang="en-US"><meta name="DCTERMS.language" content="en-US" scheme="DCTERMS.RFC4646"><meta name="DCTERMS.source" content="http://xml.openoffice.org/odf2xhtml"><meta name="DCTERMS.creator" content="Kids"><meta name="DCTERMS.issued" content="2007-10-14T03:50:55" scheme="DCTERMS.W3CDTF"><meta name="DCTERMS.contributor" content="مستخدم غير معروف"><meta name="DCTERMS.modified" content="2020-01-07T18:01:41" scheme="DCTERMS.W3CDTF"><meta name="DCTERMS.provenance" content="" xml:lang="en-US"><meta name="DCTERMS.subject" content="," xml:lang="en-US"><link rel="schema.DC" href="http://purl.org/dc/elements/1.1/" hreflang="en"><link rel="schema.DCTERMS" href="http://purl.org/dc/terms/" hreflang="en"><link rel="schema.DCTYPE" href="http://purl.org/dc/dcmitype/" hreflang="en"><link rel="schema.DCAM" href="http://purl.org/dc/dcam/" hreflang="en"></head><body style="max-width:21cm;margin-top:0cm; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; "><!--Next 'div' was a 'draw:page'.--><div id="Treatment_Overview" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T7">Treatment Overview</span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P15"><!--Next 'div' was a 'draw:text-box'.--><div style=""></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="Goals_of_Therapy" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T8">Goals of Therapy</span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.63cm;"></span><span class="T9">Reduce CVD and renal morbidity and mortality. </span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P18" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.63cm;"></span><span class="T9">Treat to BP &lt;</span><span class="T10">140/90</span><span class="T9"> mmHg or BP &lt;</span><span class="T10">130/80</span><span class="T9"> mmHg in patients with diabetes or chronic kidney disease. </span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P18" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.63cm;"></span><span class="T9">Achieve SBP goal especially in persons </span><span class="T11">&gt;</span><span class="T9">50 years of age</span><span class="T2">.</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P17"><span class="T2"></span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="Lifestyle_measures_" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">Lifestyle measures</span><span class="T1"><br></span><span class="T1"></span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P19" style="margin-left:2.011cm;"><span style="display:block;float:left;min-width:1.058cm;"></span><span class="T12">Maintain normal weight for adults (body mass index </span><span class="T13">20-25</span><span class="T12"> kg/m2)</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P19" style="margin-left:2.011cm;"><span style="display:block;float:left;min-width:1.058cm;"></span><span class="T12">Reduce salt intake to &lt;</span><span class="T13">100</span><span class="T12"> mmol/day.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P19" style="margin-left:2.011cm;"><span style="display:block;float:left;min-width:1.058cm;"></span><span class="T12">Limit alcohol consumption.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P19" style="margin-left:2.011cm;"><span style="display:block;float:left;min-width:1.058cm;"></span><span class="T12">Regular aerobic physical exercise for </span><span class="T14"></span><span class="T13">30</span><span class="T12"> minutes per day, ideally on most of days of the week but at least on three days of the week.</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P20"><span class="T15"></span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="page4" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P21"><!--Next 'div' was a 'draw:text-box'.--><div style=""></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P22" style="margin-left:2.011cm;"><span style="display:block;float:left;min-width:1.058cm;"></span><span class="T16">Consume of fresh fruit and vegetables.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P22" style="margin-left:2.011cm;"><span style="display:block;float:left;min-width:1.058cm;"></span><span class="T16">Reduce the intake of total and saturated fat .</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P23"><span class="T16"></span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="Drug_Therapy" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">Drug Therapy</span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P24"><span class="T2">A large number of drugs is available to lower BP, with different modes of action:</span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="page6" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">1. Thiazide Diuretics: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T1"><br></span><span class="T1"></span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T17">Examples:</span><span class="T2"> </span><span class="T3">bendroflumethiazide (2.5–5mg daily) and cyclopenthiazide (0.25–0.5mg daily),</span><span class="T2"> </span><span class="T3">hydrochlorothiazide (Esidrex). </span><span class="T3">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T17">Advantages:</span><span class="T2"> </span><span class="T3">cheap, no sedation effect, potentiate other drugs. &nbsp; </span><span class="T2">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="odfLiEnd">&nbsp;</span></p></li></ul></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="page7" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P21"><!--Next 'div' was a 'draw:text-box'.--><div style=""></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T2">&nbsp;</span><span class="T17">Disadvantages:</span><span class="T18"> </span><span class="T3">increased serum </span><span class="T19">cholesterol</span><span class="T3">,</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P25"><span class="T3">Impaired </span><span class="T19">glucose</span><span class="T3"> tolerance, hyperuricaemia (which may precipitate </span><span class="T19">gout</span><span class="T3">) and </span><span class="T19">hypokalaemia</span><span class="T3">. These tend to occur with higher doses of thiazide diuretics.</span></p><p class="P26"><span class="T3"></span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="Other_duretics_" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">Other duretics:</span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T20">Loop diuretics</span><span class="T3">: such as furosemide (40mg daily) do have a hypotensive effect , but are not routinely used in the treatment of essential hypertension. </span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T20">Potassium sparing diuretics</span><span class="T3">: such as amiloride (5–10mg daily) or spironolactone (50–200mg daily) are not effective agents when used alone, with the exception of spironolactone in the treatment of hypertension and hypokalaemia associated with primary hyperaldosteronism</span><span class="T21">.</span><span class="odfLiEnd">&nbsp;</span></p></li></ul></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="page9" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">2. B- blockers: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T1"><br></span><span class="T1"></span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T2">&nbsp;</span><span class="T17">mode of action:</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P25"><span class="T3">1- a fall in cardiac &nbsp; output, resulting from slower and less contractile heart.</span></p><p class="P25"><span class="T3">&nbsp;</span><span class="T3">2- central effect ~ reducing efferent sympathetic outflow. </span></p><ul><li><p class="P28" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T2">examples</span><span class="T3">: &nbsp;* </span><span class="T22">non-selective drugs: </span><span class="T3">Propranolol, Oxpronolol</span><span class="T2">. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T2">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T2"> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T22">* selective: </span><span class="T3">Atenolol, Metoprolol, bisoprolol, carvidalol. &nbsp; &nbsp; &nbsp;</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P28"><span class="T2"></span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="page10" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P21"><!--Next 'div' was a 'draw:text-box'.--><div style=""></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T2">&nbsp;</span><span class="T2">- </span><span class="T17">Advantages: </span><span class="T3">used in </span><span class="T23">angina </span><span class="T3">and </span><span class="T23">arrhythmias</span><span class="T3">,</span><span class="T3">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T3"> &nbsp; used in </span><span class="T23">thyrotoxicosis</span><span class="T3">, </span><span class="T23">combat tachycardia of vasodilators</span><span class="T3">, </span><span class="T23">lower plasma renin</span><span class="T3">, in low dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T2">&nbsp; </span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T17">&nbsp;</span><span class="T17">Disadvantages</span><span class="T2">: &nbsp;</span><span class="T3">bronchospasm, HF, fatigue, cold hands, mask hypoglycaemia in IDDM.</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P24"><span class="T2"></span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="a_3__Vasodilators_______________________________________________" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">3. Vasodilators: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T1"><br></span><span class="T1"></span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T2">1- Hydralazine: </span><span class="T3">dilates arterioles, used in hypertensive emergencies IV, useful in RF. </span><span class="T17">disadvantages</span><span class="T3">: reflex tachycardia, </span><span class="T23">SLE-like syndrome. </span><span class="T3">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </span><span class="odfLiEnd">&nbsp;</span></p></li></ul><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">&nbsp;</span><span class="T2">2- </span><span class="T24">minoxidil :(up to 50mg daily)</span><span class="T3">. </span><span class="T22">S/E :</span><span class="T3">severe </span><span class="T23">oedema</span><span class="T3">, excessive </span><span class="T23">hair growth </span><span class="T3">and coarse facial features.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T24">(If these agents are used, it is Usually in combination with a beta-blocker).</span><span class="odfLiEnd">&nbsp;</span></p></li></ul></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="a_4__Calcium_channel_blockers_" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">4. Calcium channel blockers:</span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T22">Michanism of vaction</span><span class="T3">:</span><span class="T24"> </span><span class="T3">arteriolar dilatation, and some also reduce the force of cardiac contraction.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T22">Examples:</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P25"><span class="T3">&nbsp; </span><span class="T3">1- Verapamil: has antiarrythmic activity, </span><span class="T3">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T3"> &nbsp;</span><span class="T3">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T3"> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;depress AV conduction.</span></p><p class="P25"><span class="T3">&nbsp; &nbsp;</span><span class="T3">2- Nifedipine: no effect on AV conduction </span><span class="T3">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T3"> &nbsp; &nbsp; &nbsp;may cause tachycardia and flushing </span></p><p class="P25"><span class="T3">&nbsp; </span><span class="T3">3- Amlodipine: single dose, less S/E. </span></p><p class="P28"><span class="T2"></span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="page13" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P21"><!--Next 'div' was a 'draw:text-box'.--><div style=""></div><!--Next '
            div' is a draw:frame.
        --><div style="height:10.784cm;width:23.916cm; padding:0; " id="Content_Placeholder_4" class="standard"><table border="0" cellspacing="0" cellpadding="0"><colgroup><col width="268"><col width="351"><col width="425"></colgroup><tbody><tr class="ro1"><td style="text-align:left;">&nbsp;</td><td style="text-align:left;"><p class="P29"><span class="T25">Dihydropyridines</span></p></td><td style="text-align:left;"><p class="P29"><span class="T25">Non dihydropyridines</span></p></td></tr><tr class="ro2"><td style="text-align:left;"><p class="P29"><span class="T26">Examples</span></p></td><td style="text-align:left;"><ol><li><p class="P30" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:1.428cm;">1.</span><span class="T27">Nifedipine</span><span class="odfLiEnd">&nbsp;</span></p></li></ol><p class="P31"><span class="T27">&nbsp;</span><span class="T27">2. amlodipine</span></p><p class="P31"><span class="T27">&nbsp;</span><span class="T27">3. &nbsp;felodipine</span></p></td><td style="text-align:left;"><p class="P29"><span class="T27">1. Verapamil</span></p><p class="P29"><span class="T27">&nbsp;</span><span class="T27">2. Diltiazem</span></p></td></tr><tr class="ro3"><td style="text-align:left;"><p class="P29"><span class="T26">Effect on heart rate</span></p></td><td style="text-align:left;"><p class="P29"><span class="T27">Inrease</span></p></td><td style="text-align:left;"><p class="P29"><span class="T27">Decrease</span></p></td></tr><tr class="ro1"><td style="text-align:left;"><p class="P29"><span class="T26">Site of action</span></p></td><td style="text-align:left;"><p class="P29"><span class="T27">vasculature</span></p></td><td style="text-align:left;"><p class="P29"><span class="T27">Vasculature and heart</span></p></td></tr><tr class="ro3"><td style="text-align:left;"><p class="P29"><span class="T26">Side effects</span></p></td><td style="text-align:left;"><p class="P29"><span class="T27">Headache, ankle swelling, flushing.</span></p></td><td style="text-align:left;"><p class="P29"><span class="T27">Constipation, heart failure, heart block.</span></p></td></tr></tbody></table><p><img style="height:10.784cm;width:23.916cm;" alt="" src="data:image/*;base64,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"></p></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="a_5__ACE_inhibitors_" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">5. ACE inhibitors:</span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T17">Mechanism Of action:</span><span class="T21"> </span><span class="T3">block the conversion of </span><span class="T23">angiotensin I </span><span class="T3">to </span><span class="T23">angiotensin II </span><span class="T3">, which is a potent </span><span class="T23">vasoconstrictor </span><span class="T3">.They also block the degradation of </span><span class="T23">bradykinin</span><span class="T3">,a potent vasodilator.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T22">Advantages: </span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">There is evidence that </span><span class="T28">black African </span><span class="T3">patients respond less well to ACE inhibitors unless combined with diuretics. </span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">They are particularly useful in </span><span class="T28">diabetics</span><span class="T3"> with nephropathy (they dicrease the protin urea &amp;slow disease progression). </span><span class="odfLiEnd">&nbsp;</span></p></li></ul></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="page15" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P21"><!--Next 'div' was a 'draw:text-box'.--><div style=""></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P32" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T4">and in those patients with left ventricular dysfunction, where they have been shown to improve survival. (prevent remodeling).</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P32" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T29">S/E:</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">Deterioration of renal function in those with severe bilateral renovascular </span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">Mild dry cough due to their effect on bradykinin.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">Angeoneurotic oedema.</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P25"><span class="T3"></span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="page16" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P21"><!--Next 'div' was a 'draw:text-box'.--><div style=""></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T17">Examples:</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">enalapril (10–20mg daily).</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">captopril (50–150mg daily in divided doses).</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">ramipril (2.5–10mg daily).</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">&nbsp;</span><span class="T3">lisinopril (10–20mg daily)</span><span class="odfLiEnd">&nbsp;</span></p></li></ul></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="a_6__Angiotensin-_2_receptors_antagonists_" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">6. Angiotensin- 2 receptors antagonists:</span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T30">Mechanism of action:</span><span class="T3"> </span><span class="T23">selectively</span><span class="T3"> block the </span><span class="T23">receptors for angiotensin II </span><span class="T3">does not inhibit breakdown of bradykinine, thus </span><span class="T3">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T3">does not cause dry cough.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T30">S/E: </span><span class="T3">Less than in ACE inhibitors.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P32" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T31">They are currently used for patients who Can not tolerate ACE inhibitors because of persistent cough.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T30">Examples</span><span class="T3">: losartan ,candesartan, valsartan, irbesartan and telmisartan</span><span class="T24">.</span><span class="odfLiEnd">&nbsp;</span></p></li></ul></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="a_7__Centrally_acting_agents_" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T1">7. Centrally acting agents:</span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><ul><li><p class="P17" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T30">Mechanism of action: </span><span class="T3">Reducing efferent sympathetic outflow to CVS.</span><span class="T4"> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</span><span class="T2">&nbsp;</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T30">S/E: </span><span class="T3">tiredness, depression, sedation, </span><span class="T3">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T3">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T3"> &nbsp; &nbsp; &nbsp;postural hypotension.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P27" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T30">Examples:</span><span class="T3"> </span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P32" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T4">1. Reserpine: marked depression with suicidal attempts.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P32" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T4">2. Methyldopa: </span><span class="T32">autoimmune</span><span class="T4"> haemolytic anaemia, SLE-like syndrome. Preferable antihypertensive in pregnancy.</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P32" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T4">3. Clonidine: may cause rebound HTN on </span><span class="T4">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T4"> </span><span class="T4">&nbsp; &nbsp; &nbsp; &nbsp; </span><span class="T4"> &nbsp; &nbsp; &nbsp; &nbsp; withdrall” overshoot phenomenon”</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P32" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T4">4. moxonidine.</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P27"><span class="T3"></span></p><p class="P17"><span class="T2"></span></p></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div><!--Next 'div' was a 'draw:page'.--><div id="a_8__Alpha-blockers" class="dp3"><!--Next '
            div' is a draw:frame.
        --><div style="height:3.386cm;width:20.742cm; padding:0; " id="Title_1" class="P6"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P14"><span class="T33">8. Alpha-blockers</span></p></div></div><!--Next '
            div' is a draw:frame.
        --><div style="height:13.546cm;width:23.917cm; padding:0; " id="Content_Placeholder_2" class="P11"><!--Next 'div' was a 'draw:text-box'.--><div style=""><p class="P25"><span class="T30">Mechanism of action: </span><span class="T3">post synaptic α1receptor blockade with resulting vasodilatation.</span></p><ul><li><p class="P26" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T30">Examples:</span><span class="T22"> </span><span class="T3">the newer agents:</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P26" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">doxazosin(1–4mgdaily).</span><span class="odfLiEnd">&nbsp;</span></p></li><li><p class="P26" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T30">Advantages:</span><span class="T3"> (pheochromocytoma/ benign prostatic hyperplasia).</span><span class="odfLiEnd">&nbsp;</span></p></li></ul><p class="P25"><span class="T3"></span></p><ul><li><p class="P26" style="margin-left:0.001cm;"><span style="display:block;float:left;min-width:0.952cm;"></span><span class="T3">Labetalol is anagent That has combined alpha-and beta- blocking properties,but is not commonly used, except in pregnancy-induced hypertension.</span><span class="odfLiEnd">&nbsp;</span></p></li></ul></div></div></div><div style="clear:both; line-height:0; width:0; height:0; margin:0; padding:0;">&nbsp;</div></div></div></div></div></div></div></div></body></html>
------MultipartBoundary--Vu8lxH1io5xnESpoEpOt15FWjOlBHgKeVZoPzvcDIJ----
Content-Type: text/css
Content-Transfer-Encoding: binary
Content-Location: cid:css-37ae82ae-fc0a-4716-88c5-194d8658c832@mhtml.blink

@charset "utf-8";

@page { }

table { border-collapse: collapse; border-spacing: 0px; empty-cells: show; }

td, th { vertical-align: top; font-size: 12pt; }

h1, h2, h3, h4, h5, h6 { clear: both; }

ol, ul { margin: 0px; padding: 0px; }

li { list-style: none; margin: 0px; padding: 0px; }

span.footnodeNumber { padding-right: 1em; }

span.annotation_style_by_filter { font-size: 95%; font-family: Arial; background-color: rgb(255, 240, 0); margin: 0px; border: 0px; padding: 0px; }

span.heading_numbering { margin-right: 0.8rem; }

* { margin: 0px; }

.gr1 { font-size: 18pt; font-style: normal; font-weight: normal; line-height: 100%; margin: 0cm; padding: 0.125cm 0.25cm; text-indent: 0cm; text-shadow: none; font-family: "Liberation Sans"; min-height: 1.485cm; text-decoration: none !important; }

.gr2 { font-size: 18pt; font-style: normal; font-weight: normal; line-height: 100%; margin: 0cm; padding: 0.125cm 0.25cm; text-indent: 0cm; text-shadow: none; font-family: "Liberation Sans"; min-height: 1.485cm; text-decoration: none !important; }

.gr3 { font-size: 24pt; font-family: "Liberation Serif"; }

.standard { font-size: 18pt; font-family: "Liberation Sans"; padding: 0.125cm 0.25cm; margin: 0cm; line-height: 100%; text-indent: 0cm; font-style: normal; text-shadow: none; font-weight: normal; text-decoration: none !important; }

.P1 { font-size: 14pt; }

.P10 { margin: 0.141cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; font-size: 32pt; text-align: left !important; }

.P11 { font-size: 32pt; text-align: left !important; }

.P12 { font-size: 14pt; text-align: left !important; }

.P13 { margin-top: 0cm; margin-bottom: 0cm; line-height: 100%; writing-mode: lr-tb; font-size: 14pt; text-align: right !important; }

.P14 { margin-top: 0cm; margin-bottom: 0cm; line-height: 100%; writing-mode: lr-tb; text-align: left !important; }

.P15 { margin: 0.226cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; color: rgb(0, 0, 0); font-family: Arial; font-size: 32pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-align: left !important; text-decoration: none !important; }

.P17 { margin: 0.226cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P18 { margin: 1.129cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P19 { margin: 0.494cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P2 { font-size: 14pt; }

.P20 { margin: 0.381cm 0cm 0cm 0.953cm; line-height: 100%; text-indent: -0.952cm; writing-mode: lr-tb; text-align: center !important; }

.P21 { margin-top: 0cm; margin-bottom: 0cm; line-height: 100%; writing-mode: lr-tb; color: rgb(255, 255, 255); font-family: Arial; font-size: 44pt; letter-spacing: normal; font-style: normal; font-weight: bold; text-align: left !important; text-decoration: none !important; }

.P22 { margin: 0.564cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P23 { margin: 0.226cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P24 { margin: 0.226cm 0cm 0cm 0.953cm; line-height: 100%; text-indent: -0.952cm; writing-mode: lr-tb; text-align: left !important; }

.P25 { margin: 0.198cm 0cm 0cm 0.953cm; line-height: 100%; text-indent: -0.952cm; writing-mode: lr-tb; text-align: left !important; }

.P26 { margin: 0.198cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P27 { margin: 0.198cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P28 { margin: 0.226cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P29 { margin: 0.183cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P3 { font-size: 14pt; text-align: right !important; }

.P30 { margin: 0.183cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P31 { margin: 0.183cm 0cm 0cm 1.429cm; line-height: 100%; text-indent: -1.428cm; writing-mode: lr-tb; text-align: left !important; }

.P32 { margin: 0.169cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; text-align: left !important; }

.P4 { font-size: 14pt; text-align: right !important; }

.P5 { margin-top: 0cm; margin-bottom: 0cm; line-height: 100%; writing-mode: lr-tb; font-size: 44pt; text-align: left !important; }

.P6 { font-size: 44pt; text-align: left !important; }

.P7 { margin: 0.226cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; font-size: 32pt; text-align: left !important; }

.P8 { margin: 0.198cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; font-size: 32pt; text-align: left !important; }

.P9 { margin: 0.169cm 0cm 0cm; line-height: 100%; text-indent: 0cm; writing-mode: lr-tb; font-size: 32pt; text-align: left !important; }

.ce1 { padding: 0.127cm 0.254cm; border-width: 0.0169cm 0.0169cm 0.0529cm; border-style: solid; border-color: rgb(255, 255, 255); }

.ce2 { padding: 0.127cm 0.254cm; border-width: 0.0169cm; border-style: solid; border-color: rgb(255, 255, 255); }

.ce3 { padding: 0.127cm 0.254cm; border-width: 0.0169cm; border-style: solid; border-color: rgb(255, 255, 255); }

.co1 { width: 6.138cm; }

.co2 { width: 8.043cm; }

.co3 { width: 9.736cm; }

.ro1 { height: 1.271cm; }

.ro2 { height: 3.669cm; }

.ro3 { height: 2.287cm; }

.T1 { color: rgb(255, 255, 255); font-family: Arial; font-size: 44pt; letter-spacing: normal; font-style: normal; font-weight: bold; text-decoration: none !important; }

.T10 { color: rgb(255, 0, 0); font-family: "Arial Narrow"; font-size: 32pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T11 { color: rgb(0, 0, 0); font-family: "Arial Narrow"; font-size: 32pt; letter-spacing: normal; font-style: normal; text-decoration: underline; font-weight: normal; }

.T12 { color: rgb(0, 0, 0); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T13 { color: rgb(255, 0, 0); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T14 { color: rgb(0, 0, 0); font-family: Symbol; font-size: 28pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T15 { color: rgb(0, 0, 0); font-family: Arial; font-size: 54pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T16 { color: rgb(0, 0, 0); font-family: Arial; font-size: 32pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T17 { color: rgb(0, 0, 0); font-family: Arial; font-size: 32pt; letter-spacing: normal; font-style: normal; text-decoration: underline; font-weight: normal; }

.T18 { color: rgb(0, 0, 0); font-family: Arial; font-size: 32pt; letter-spacing: normal; font-style: normal; text-decoration: underline; font-weight: bold; }

.T19 { color: rgb(255, 0, 0); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T2 { color: rgb(0, 0, 0); font-family: Arial; font-size: 32pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T20 { color: rgb(28, 144, 86); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T21 { color: rgb(0, 0, 0); font-family: Arial; font-size: 32pt; letter-spacing: normal; font-style: normal; font-weight: bold; text-decoration: none !important; }

.T22 { color: rgb(0, 0, 0); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; text-decoration: underline; font-weight: normal; }

.T23 { color: rgb(10, 10, 255); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T24 { color: rgb(0, 0, 0); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; font-weight: bold; text-decoration: none !important; }

.T25 { color: rgb(255, 255, 255); font-family: "Times New Roman"; font-size: 26pt; letter-spacing: normal; font-style: normal; font-weight: bold; text-decoration: none !important; }

.T26 { color: rgb(0, 0, 0); font-family: "Times New Roman"; font-size: 26pt; letter-spacing: normal; font-style: normal; text-decoration: underline; font-weight: normal; }

.T27 { color: rgb(0, 0, 0); font-family: "Times New Roman"; font-size: 26pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T28 { color: rgb(56, 73, 45); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T29 { color: rgb(0, 0, 0); font-family: Arial; font-size: 24pt; letter-spacing: normal; font-style: normal; text-decoration: underline; font-weight: normal; }

.T3 { color: rgb(0, 0, 0); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T30 { color: rgb(0, 0, 0); font-family: Arial; font-size: 28pt; letter-spacing: normal; font-style: normal; text-decoration: underline; font-weight: bold; }

.T31 { color: rgb(0, 0, 0); font-family: Arial; font-size: 24pt; letter-spacing: normal; font-style: normal; font-weight: bold; text-decoration: none !important; }

.T32 { color: rgb(10, 10, 255); font-family: Arial; font-size: 24pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T33 { color: rgb(255, 255, 255); font-family: Arial; font-size: 44pt; letter-spacing: normal; font-style: italic; font-weight: bold; text-decoration: none !important; }

.T4 { color: rgb(0, 0, 0); font-family: Arial; font-size: 24pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T5 { color: rgb(0, 0, 0); font-family: Arial; font-size: 20pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T6 { color: rgb(0, 0, 0); font-family: "Times New Roman"; font-size: 14pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.T7 { color: rgb(255, 255, 255); font-family: "Arial Rounded MT Bold"; font-size: 54pt; letter-spacing: normal; font-style: italic; font-weight: bold; text-decoration: none !important; }

.T8 { color: rgb(255, 255, 255); font-family: Andalus; font-size: 54pt; letter-spacing: normal; font-style: italic; font-weight: bold; text-decoration: none !important; }

.T9 { color: rgb(0, 0, 0); font-family: "Arial Narrow"; font-size: 32pt; letter-spacing: normal; font-style: normal; font-weight: normal; text-decoration: none !important; }

.dp1 .dp2 .dp3 .P16 { }
------MultipartBoundary--Vu8lxH1io5xnESpoEpOt15FWjOlBHgKeVZoPzvcDIJ------
